Loading...
The U.S. FDA has approved labeling additions to the boxed warnings for systemic fluoroquinolones to include disabling and potentially irreversible serious adverse reactions that have occurred together, including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects. Additionally, the boxed warning tells healthcare providers that because of these serious adverse reactions, fluoroquinolones should be reserved for use in patients with no alternative options for uncomplicated urinary tract infections, acute bacterial exacerbation of chronic bronchitis, or acute bacterial sinusitis. Otherwise, the risks outweigh the benefits for these indications. The FDA also updated warnings in other parts of the medication l…